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Abstract 
Translational research tries to apply findings from basic science to enhance human health and well‑being. Many 
phases of the translational research may include non‑medical tasks (information technology, engineering, nano‑
technology, biochemistry, animal research, economy, sociology, psychology, politics, and so on). Using common 
bioethics principles to these areas might sometimes be not feasible, or even impossible. However, the whole process 
must respect some fundamental, moral principles. The purpose of this paper is to argument the need for a different 
approach to the morality in translational bioethics, and to suggest some directions that might be followed when 
constructing such a bioethics. We will show that a new approach is needed and present a few ethical issues that are 
specific to the translational research.
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Background
Translational science is a novel concept, whose main 
purpose is to categorize practical, outcome-oriented 
research [1]. In healthcare, translational research can be 
viewed as research on human specimens, whose findings 
may inform basic science research and lead to a trans-
fer of the results towards clinical therapeutics and novel 
healthcare policies; its definition seems however to be an 
ever evolving phenomenon; if initially it referred to the 
bench-to-bedside enterprise of using information from 
basic sciences to produce new treatment alternatives 
for patients [2], nowadays it is defined by a process that 
starts with fundamental research (genes, molecular pro-
cesses, biochemical pathways) and ends at a macro level 
(social healthcare, access to healthcare, access to educa-
tion, and so on) [3]. Moreover, some authors considered 
that translational process should not start with funda-
mental research, as this approach rarely succeeds, but 
rather from clinical medicine—the so-called bedside to 
bench to bedside approach. A classical example to show 
the usefulness of this approach is represented by the 
development of balloon angioplasty by Gruentzig [4]. A 
more recent example is represented by T cell therapy—T 
cells have various roles in cell-mediated immunity, being 
able, among others to differentiate between healthy and 
abnormal (including neoplastic) cells, and is involved in 
HIV infection. This clinical knowledge has recently been 
brought to the “bench” by a research team lead by dr. 
Marson, who, by editing the genome of human T (CD4+) 
cells using a CRISPR/Cas9 ribonucleoprotein delivery 
method, caused up to 40 % of the cells to lose high level 
cell surface expression of CXCR4 [5], which could open 
new therapeutic possibilities in oncology, autoimmunity 
or infectious diseases.
For the purposes of this article we will try to define the 
translational process as containing three main elements: 
phases, gaps, and data transfer; therefore, when analys-
ing ethical issues determined by translational research we 
will consider them as appertaining to either an element 
of the translational process (phase, gap, data transfer), or 
the process of translational research itself (see Fig.  1—
modified after [3, 6, 7], and Table  1 for some examples 
of ethical issues depending on the element of the transla-
tional process).
Initially translational research was considered as con-
taining two main phases: T1—bench-to-bedside, in 
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which new discoveries from the laboratory could be 
translated towards clinical research (proof of concept, 
phase I and II clinical trials) and T2, in which these appli-
cations were translated in clinical practice (phase III 
clinical trials, studies of clinical efficacy and development 
of clinical guidelines). Recently the process was further 
developed by the addition of other stages; therefore, the 
most recent models contain either four or six transla-
tional phases [3, 6] and may or may not include the bed-
side-to-bench approach. For the purpose of this article, 
we will use the six-phase approach shown in Fig. 1. The 
six-phase approach considers that translational research 
starts with fundamental research and ends with develop-
ing and implementing social/economical policies deter-
mined by the results obtained in the process.
Between each adjacent set of phases is a gap, or road-
block, which refers to the lack of funding/support needed 
for the progression to the next [8]. The most important 
gap is between T0 and T1, called valley of death because 
most fundamental research studies do not go beyond it 
(therefore to not enter the clinical phases). According 
to Pienta these translational gaps are dependent upon 
the successful management of four main risks: scientific, 
intellectual property, regulatory, and market [8].
In the translation process, the transfer of information 
from one study to the next one characterizes data transfer 
[8]. These transfers occur either within phases or between 
phases (usually adjacent, but not always). The type of data 
transferred depends on the location of the transfer on 
the translational research process. For example the data 
Fig. 1 Translational research—from fundamental research to developing policies (based on information retrieved from [61] and [3])
Table 1 Examples of ethical issues depending on the translational process elements
Translational process Ethical issues Examples
Phases Mainly derived from research ethics—animal  
bioethics, research of clinical trials, etc.
Informed consent in clinical trials for the develop‑
ment of assistive devices
Social injustice and discrimination caused by using 
neural prostheses to enhance neurocognitive 
processes [62]
Gaps Ethics of resource allocation Allocation of public research grants for either “safer” 
research, with high chances of success but limited 
healthcare impact versus unconventional research 
with smaller chances of success but greater poten‑
tial healthcare impact
Data transfer Research misconduct, data confidentiality Sharing of data obtained from neural sensory input 
that is used in modelling software medical solu‑
tions [63, 64]
Process of translational research as a whole Social justice, translational approach of risks, data 
sharing and protection
Conducting medical trials in developing countries
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that is transferred in within the first two phases is usually 
newly created data, which stays at the basis of the whole 
translational research process. The information created in 
this stage is structured in a way that can be easily trans-
ferred toward clinical research. For example, suppose that 
an investigator discovers a new heart receptor for angio-
tensin in cell cultures. This information, which is newly 
created, is transferred to another preclinical investigator, 
who might test its clinical consequences on animal mod-
els. The created data from this study is then transferred 
to a pathologist who will test the effect of the recep-
tor on the pathological human heart. The data is then 
transferred to another researcher who might be involved 
in developing a drug that could be helpful for that spe-
cific cardiac pathology. All this transfer of newly created 
data happens in Phase 0. Next, the information could be 
transferred to a clinical investigator who will try a Phase 
0 study on humans with the above-mentioned drug. 
Each data transfer is directed toward a certain group 
of individuals (that can be anything from a small group 
of researchers to a major population group). The size of 
the group that receives the transmitted data increases in 
size with the advancement of translational process. For 
example, the target group for transferring newly created 
knowledge (during fundamental research) is represented 
by investigators involved in basic and subsequently clini-
cal research, whose number is usually very small. When 
going from Phase 2 to Phase 3 the knowledge will be 
transferred to clinicians, patients, epidemiologists, and 
so on, a much larger target group. Data transfer is usu-
ally done step by step in translational research. However, 
there are instances in which the process can skip one or 
more phases. For example, detecting a gene that is often 
associated with cancer might lead directly to dissemina-
tion of the information, or even public health initiatives, 
without going through T1 and T2 phases.
According to the Merriam-Webster dictionary, bioeth-
ics is defined as a discipline dealing with ethical implica-
tions of biological research and applications, especially 
in medicine. This definition is very broad, as it includes 
biological research (medical research, animal research, 
environment research), and medical practice. However, 
it is limited when trying to analyse recent developments 
in medical research, in which non-biological components 
are starting to have a bigger importance—information 
technology (IT) development, nanotechnologies, engi-
neering, and so on (see Table  2 for an example). These 
developments lead to two important questions that must 
be answered before defining the scope of translational 
bioethics: (1) Should we analyse translational research 
ethics in direct relation to the steps/phases, or should we 
develop a more general set of bioethical guidelines guid-
ing the entire translational research process?, and (2) 
Should we consider translational research as a subtype of 
biomedical research, or should we develop a new set of 
bioethical tools specifically directed to the often transdis-
ciplinary characteristics of translational research?
Table 2 Example of translational research—assistive device helping blind people to see with the aid of audio and haptic 
inputs
The completion of each preceding task is needed for the development of the next task
Italic emphasized tasks are biomedical; non-emphasized tasks have a significant non-biomedical component
Phase Aims Tasks
T0 Identifying the way sensory inputs overlay at the brain level 1. Neuroscience
2. Prospective/observational studies
T1 Developing audio and haptic sensors
Developing software to aid the translation of audio and haptic sensors 
to visual inputs or aids
3. Proof of concept
4. IT development
T2 Studying the usefulness of the device
Measuring neural/sensory inputs/outputs
5. Using beta testers in closed/open environments (NOT research 
subjects)
6. Possible medical research (bio‑feedback)
T3 Disseminating the results to patients and clinicians 7. Certification of the device (analysis of the risk–benefit ratio)—might be 
needed a clinical trial
8. Increase awareness about the technology (marketing)
9. Promote the technology to stakeholders
10. Comparing the effectiveness of the technology with others at a popula-
tion level, identifying possible limitations/adverse reactions
T4 Changing public health policies and behaviors beyond the effects of 
the treatment
11. Shift from intervention to prevention (public health campaigns, 
recommendations about lifestyle changes based on the results 
obtained from the previous phases)
T5 Social policies 12. Decreasing societal disparities, improving access to healthcare for 
underdeveloped communities, interacting with cities in order to 
maximize the input
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The purpose of this article is to analyse whether a bio-
ethics approach based on current, healthcare centred 
principles, is enough to allow a comprehensive model for 
the morality of translational research.
Should we analyse translational research in direct 
relation to the steps/phases, or should we develop 
a more general set of bioethical guidelines guiding 
the entire translational research process?
Most articles dealing with translational bioethics limit 
their analysis to one or few steps of the translational 
research process. For example Kimmelman [9] analysed 
the biases generated by risk assessment of clinical tri-
als by the Ethics Review Boards. Shapiro and Layde 
analysed case scenarios in different phases of trans-
lational research, in order to identify the critical role 
of bioethics in each stage of clinical and translational 
research [10]. Bærøe considered that translational eth-
ics includes two main discussion topics: (1) the ethics 
of translational biomedical research, in which we must 
analyse the various practical scenarios derived from the 
translational research, and (2) the internal gap between 
theory and practice within the field of ethics itself [11]. 
Hyun and Kimmelman made a phase oriented ethical 
analysis in translational gene transfer research [12]. The 
first topic is a typical step-by-step analysis of research 
ethics issues, while the second is a more general issue, 
recognized by some authors in the last years, related to 
the development of a rift between theoretical bioethics 
and its implementation in medical practice [13, 14]. The 
translational research process contains however not only 
phases but also gaps between phases, and transfer of 
knowledge in which the results are translated from one 
phase to another, translation that could also pose ethical 
issues. To illustrate this, we will present a situation gen-
erated by translating information from Phases 1 and 2 to 
Phase 5 from Table  3, in which is detailed the transla-
tional process involving in vitro fertilization with sperm 
procured from the deceased [15]. Recently a series of 
articles was published that supported the idea of using 
a presumed consent model for this technique mean-
ing that, in the absence of a refusal from the deceased 
husband before death, the wife could use the posthu-
mously harvested sperm for in  vitro fertilization [16, 
17]. Tremellen and Savulescu [16] used a predominantly 
theoretical approach to the argumentation in favour of 
presumed consent, while Hans [17] based his conclu-
sion on a sociological study that supported this option. 
The translation presented by both articles (from clinical 
practice to social health policy) is associated with ethical 
issues. In order for a theoretical approach to be allowed 
for developing social policies, it should be based on a set 
of accepted general moral guidelines and an exhaustive 
analysis of the issue (including legal, social, economical 
and anthropological issues). An analysis not based on 
the above-mentioned issues could lead to wrong conclu-
sions, which implemented in clinical practice might lead 
to clearly unethical actions. For example, Tremellen and 
Savulescu, arguing for a need of a presumed consent on 
the issue, stated that:
In our view, it can be argued that the welfare of the liv-
ing is a far more important consideration than splitting 
hairs over degrees of consent and infringement of alleged 
autonomous rights of a deceased person. It is important to 
remember that the dead person no longer exists, so at that 
time deceased cannot have interests or be autonomous. 
Any ‘respect’ is related to creating policies that ensure 
that the living now are not harmed or fail to have their 
Table 3 Example of translational research—in vitro fertilization after posthumous sperm procurement
Italic emphasized tasks are biomedical; non-emphasized tasks have a significant non-biomedical component
Phases Aims Tasks
T0 Identifying characteristics and viability of semen after death Sampling postmortem reproductive products
T1 Testing in real environments Case reports, a few hundred cases worldwide—procreative autonomy, 
consent from the dead, moral status of the embryo, conflicts of interests
T2
T3 Disseminating the results to patients and clinicians Increased awareness about the technique (scientific journals, mass media)
Comparing the effectiveness of the technology with other IVF tech‑
niques
T4 Changing public health policies and behaviors beyond the effects of 
the treatment
Establishing guidelines regarding IVF after PSP
Promoting the technique outside classical scenarios (sampling for 
fertilization other persons than the wife)
T5 Social policies Generalizing the concept of presumed consent for PSP
Decreases the number of unfertile couples caused by the death of a 
husband
Increases the birth rate
Changes in the resource allocation for ARTs
Page 5 of 10Hostiuc et al. J Transl Med  (2016) 14:16 
autonomous wishes respected—that is satisfied by an opt 
out system for posthumous conception. Put succinctly, if 
you don’t want it, sign out now. (page 9) [16].
Most Civil Codes, at least from Europe, consider that 
a person, even if it has died, can exert posthumously a 
series of rights, through testamentary dispositions. This 
means that the person retains some “autonomous rights”. 
The Declaration of Geneva (2006) and the World Medi-
cal Association (WMA) Code of Ethics (2006) both state 
that medical confidentiality must be maintained after the 
patient dies. Medical confidentiality is based, at least par-
tially, on the right to autonomy (to autonomously choose 
how to share medical information about one self ). Most 
countries consider that organ harvesting from deceased 
should be based on a previous consent of the donor, or 
at least on the consent of the family (the opt in variant 
for organ donation, present in most countries includ-
ing Germany, Japan, Romania). There are however some 
counties, especially in Europe, which have a form of pre-
sumed consent (opt out) procedure for organ donation 
(including Austria, Croatia, Spain, Belgium). The type of 
procedure (opt-in or opt-out) seems to be a very impor-
tant reason for organ donation, as revealed by the rates 
from Germany to Austria, two countries with highly sim-
ilar cultures—in Germany, a country that preferred the 
opt-in method, the consent rate is around 12 % while in 
Austria, a country that preferred the opt-out method, the 
consent rate is almost 100 % [18–21].
Therefore, we cannot really talk, at least in current 
medical practice, about the absence of autonomy after 
the death of the patient. In our opinion, using subjective 
argumentation, not based on current legislative and gen-
erally accepted practices in order to support the devel-
opment of a health-care policy is unethical, as it may be 
considered a form of manipulation, exercised over stake-
holders. This manipulation could lead to the creation 
of health-care policies that would have to be applied in 
clinical practice by physicians, who will be put in a posi-
tion to respect either a fundamental code of ethics or 
deontology (again, at least in Europe, many countries 
have Physicians’ Codes of Ethics that rely heavily on the 
WMA Code of Ethics), or the national health care poli-
cies. By not respecting the healthcare policies, they could 
do something illegal, while by not respecting the deonto-
logical/ethical norms of the medical practice they would 
do something immoral. Hans used a sociological survey 
that showed an increased support for posthumous sperm 
procurement [17]. This approach again contradicts fun-
damental ethical principles in medical practice. The 
WMA Code of Ethics states: “A physician shall respect 
the right of the patients.” [22]. Imposing a certain proce-
dure based on statistical analysis (what most of the popu-
lation might want) contradicts the principle of autonomy 
in medicine, which basically states that a person should 
be able to make informed decisions about one-self. For 
example, most patients would agree to suffer a surgical 
intervention for peritonitis (so statistically there is an 
agreement about accepting the procedure if they were 
the patients needing that intervention); however, if they 
are conscious, they are still required to give their con-
sent before entering into the surgery, and are allowed 
to refuse it. Again, the patient status of the deceased is 
debatable; however, as the medical codes of ethics recog-
nize some autonomy related rights for deceased patients, 
it is assumed that they have at least, a form of autonomy, 
that they could very well exercise before dying. So, in 
order to respect the autonomy of the patient an opt-in 
alternative to medical procedures after death should be 
imposed, not an opt-out variant. The patient should be 
able to make informed decisions about what will happen 
to him/her after death; if this does not happen, unsub-
stantiated assumptions about his/hers agreements for 
various medical procedures should not be allowed, as 
they are legally and morally problematic (affecting his/
hers self-determination).
A very hot topic in translational research, which pre-
sents perfectly the intricacies and limits of bioeth-
ics in translational research is represented by stem cell 
research. Tremendous progress is made every year, 
requiring a permanent redefinition of what is ethically 
permissible in stem cell research, and what topics remain 
actual in this field. For example in the 1990s, major 
issues in this area were focused on obtaining embryonic 
stem cell research from aborted fetuses or cloning for 
the creation of embryonic stem cells for transplantation 
[23–28]. In the next decade the number of articles in this 
area exploded, a more than tenfold increase being iden-
tified on Web of Knowledge; the articles began to deal 
with more specific aspects of stem cells ethics, includ-
ing patents, commercialization, creation of adult cell 
lines, creation of part animal stem cells, etc. [29–37]. 
From 2011 to 2015 a shift is again seen, this time from 
embryonic stem cells ethics to adult or induced pluri-
potent stem cells (IPSC) ethics [38–42]. When working 
with IPSCs researches do not have to analyse the moral-
ity of using embryos, and therefore debates around abor-
tion, moral status of the embryo, commercialization of 
human embryos, teleology of the human embryo are not 
relevant. They do have however important ethical issues 
to deal with. For example IPSCs are known to form tera-
tomas when injected in immunodeficient mice [43, 44]. 
Therefore, IPCSs may have the potential to generate 
human cancers when injected to treat various diseases. 
This could lead to ethical debates regarding the primor-
diality of beneficence (physicians have a moral duty to 
help their patients) versus non-maleficence (physicians 
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have a moral obligation not to do harm to their patients). 
Uncertainty related to the long term benefits or risks is 
another ethical issue related to IPCS—should physicians 
recommend such a therapy taking into account that the 
long term benefits and risks are not fully quantifiable? 
[42]. Should IPCSs used as an alternate method to gam-
ete donation in assisted reproductive technologies? [45].
As shown in Table 1, translational research has ethical 
issues related to any of its four main elements (phases, 
gaps, transfer of knowledge, the process itself ). Even if 
all are potentially equally important, most researchers 
in this area focused solely on the phase related ethical 
issues [1, 2, 9–12, 46–54], which, in our opinion, is not 
enough for a comprehensive ethical analysis of transla-
tional research. However, by analysing all ethical related 
issues associated with all its elements, and taking into 
account the high variability of translational research, we 
could easily find ourselves in the position of considering 
that translational bioethics should deal with most, if not 
all, imaginable bioethical issues. This approach, even if 
exhaustive, does not grasp the particularities of the trans-
lational research bioethics. Therefore, our opinion is that 
we should try to analyse more specifically what makes 
translational research unique from other forms of bio-
medical research, and to draw a series of general ethical 
norms with a wide applicability in this field.
Should we consider translational research as a 
subtype of biomedical research, or should we 
develop a new set of bioethical tools specifically 
directed to the interdisciplinary characteristics 
of translational research?
Most codes of research ethics require all biomedical 
research to be carried out under the supervision of a cer-
tified physician or other properly qualified health care 
professional. For example, the Helsinki Declaration, Art 
12 states that:
Medical research involving human subjects must be 
conducted only by individuals with the appropriate eth-
ics and scientific education, training and qualifications. 
Research on patients or healthy volunteers requires the 
supervision of a competent and appropriately qualified 
physician or other health care professional. (Article 12) 
[55].
However, there are instances of translational research 
in which most of the phases contain non-medical studies/
activities. See Table 2 for such an example, in which the 
researchers are trying to develop an assistive device for 
visually impaired people by using haptic and audio sig-
nals; the translational process include 12 steps, of which 
only four can be considered as biomedical research. Most 
of them are either IT development or public health related 
(social policies, interactions with local administration, 
and so on). If we consider them to be biomedical research, 
they should comply to all legal and ethical requirements 
of biomedical research, which means, among others, 
obtaining consent from the subjects, obtaining an Ethi-
cal Committee approval for the study, supervision by 
medical personnel, and so on. Let us take an example 
from Table  2. Suppose that one step of this research is 
to develop a medical device constructed as a wearable 
head unit that enables the user to precisely determine 
the spatial characteristics of sounds. For this, some test-
ers must walk around the lab and be subjected to various 
sound patterns. The responses of the testers are recorded. 
By relating this research to the principles from the Hel-
sinki Declaration this activity fits within the purposes of 
biomedical research: “The primary purpose of medical 
research involving human subjects is to understand the 
causes, development and effects of diseases and improve 
preventive, diagnostic and therapeutic interventions 
(methods, procedures and treatments)” [55] because its 
purpose is to develop a therapeutic intervention for vis-
ually impaired people. However, the same activity can 
be considered a development phase for an IT product. 
How should the researchers consider this activity? If is it 
considered biomedical research, it must comply with all 
medical research regulations that would maximize the 
protection of the testers (physically, ethically and legally), 
but also increase the costs maybe tenfold. The precautions 
may be excessive and unnecessary as the risks are minimal 
and can be safely handled by other means; e.g., work pro-
tection, and the testers are competent to make decisions 
about the precautions needed for the study. If it is con-
sidered an IT development phase—instead of a biomedi-
cal research—the importance of the risks will be lowered 
because a risk assessment might not be performed before 
starting the tests. The issues related to protection and 
sharing of personal data (e.g., data obtained from the 
records of the responses of the subjects) might also be 
minimized. Our opinion is that the problem here is deter-
mined by the phase analysis of translational research. By 
using it we tend to reffer to biomedical/research ethics 
guidelines even in instances in which they are too strict, in 
order to apparently maximize the protection for subjects/
patients/citizens. However, this apparent strictness affects 
the efficiency of the phases that are not actually biomedi-
cal research, by imposing time consuming and highly 
expensive tasks. A more holistic approach to bioethics in 
translational research might be of use for the whole pro-
cess aimed toward minimizing the risks for subjects, other 
involved persons, and the society as a whole. This should 
be associated with a clear definition of what biomedical 
research is, and of course with imposing additional safe-
guards for activities that will comply with the definition of 
biomedical research. For the above example, we could do 
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a risk assessment before the practical phases and develop 
methods for minimizing/removing the risks by a com-
mittee consisting of both investigators with healthcare 
specialization and non-medical personnel. Afterwards, 
the non-medical tasks will be handled according to the IT 
development principles, in full compliance with the risk 
mitigation methods established in the initial phase.
Some proposals for general ethical principles 
guiding translational research
Consequentialist analysis of the translational research 
process
Before starting a translational research the investigators 
should analyse potential effects not only for the subjects’ 
population, but also on a more general level. Translational 
research should not be performed only for scientific curi-
osity or prestige for the researchers but also for the ben-
efit of the society. This statement might be considered as 
limiting fundamental research, which is not the case. The 
main purpose of translational research is to translate fun-
damental research to clinical practice and beyond. There-
fore the above principle should only apply to research 
that is build having in mind a translational process. For 
example, suppose that an investigator wishes to study a 
gene involved in hypertension. In order to translate this 
research into clinical practice he should not think only 
about results derived from the genetic analysis, but also 
on potential clinical applications (gene therapy, or devel-
oping a drug that interacts with the product of the gene 
and decreases blood pressure). He must also consider the 
population groups that may benefit from the research, 
the potential cost and the location of the clinical stud-
ies. He must reason whether a product is actually needed 
keeping in mind the multitude of antihypertensive drugs 
and whether such a drug can become a de facto standard 
in the treatment of hypertensive patients or if it will only 
be useful for selected subgroups. Furthermore, he must 
also consider whether the costs associated with the trans-
lational research process would not be better spend for 
another drug, and so on. Such an analysis will allow us 
to see not only the immediate consequences of the study, 
but also future developments, and should allow a better 
analysis of its clinical usefulness. Moreover, this analy-
sis will allow a better management of medical research 
funds, with a targeted increase of funds for medical 
issues lacking enough financing (a better resource alloca-
tion, therefore maximizing the benefit resulted from the 
available finances for biomedical research).
Translational analysis of the risks associated with the 
research
If we are to analyse the risks for each phase we might 
either stop the research if the risks are too high, or to 
continue the research if they are minimal, irrespective of 
the overall risks that might be caused by that particular 
research. For the first variant the easiest example comes 
from oncology. Developing a new drug comes with very 
high risks for Phase I subjects. If we were to consider only 
the risks to which the participants are subjected to, we 
might stop the research, as the risks might be considered 
too high. However, without the research, and without the 
data obtained form this step, the morbidity and mortal-
ity decrease associated with the use of that particular 
drug, would not happen. For the second variant, we can 
imagine a phase II clinical trial in which the drug seems 
to have significantly better results compared with other 
drugs with only an insignificant increase of the risks. 
These risks however might become important (either 
increases in number or the detection of rare adverse reac-
tions with severe consequences) if we were to use a larger 
number of subjects, risks that were identified by other 
studies analysing similar drugs. Therefore, by not taking 
into account the increase in statistical power that comes 
with increasing the numbers of subjects/patients and the 
data from similar pharmacological agents, we minimize 
the importance of the potential risks associated with the 
tested drug. Thus, before starting a translational research 
process, we should do a more exhaustive analysis of the 
risks associated with it, even if they are only potential, 
or only suggested by similar studies. The analysis of risk 
within the translational process should be done using a 
consequentialist approach, because minimizing the risks 
for the subjects and even at a population level should be 
an important objective of translational bioethics.
Social justice
In order to increase the degree of social justice caused 
by a particular translational research, there should be a 
correspondence between where the research is done, by 
whom, with which finances, on which subjects and for 
which potential beneficiaries, while protecting at the 
same time the vulnerable populations (women, children, 
psychiatry patients, prisoners, people from developing 
countries, and so on). Suppose for example that an inves-
tigator wishes to develop a very potent antihypertensive 
drug, whose market cost would be 10.000 USD. For such 
a drug the potential beneficiaries would be, at least in the 
first instance, people from developed countries. There-
fore, it should not be allowed for this type of clinical trial 
to take place in a developing country, where there would 
be a very low number of potential beneficiaries. Here we 
see how the consequentialist analysis of potential appli-
cations of translational research would limit the inclu-
sion of subjects from developing countries, based on 
more objective criteria (impossibility to pay for the medi-
cal product). Currently there are a lot of clinical trials 
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conducted in developing countries, which would benefit 
patients mainly from developed countries, that clearly 
contradicts the bioethical principle of justice, according 
to whom, in the widest normative sense, equals should be 
treated as equals, and un-equals, un-equal. By perform-
ing clinical trials in developing countries, for drugs that 
would be primarily used in developed countries we tend 
to treat equals (human beings), un-equally (some suffer 
the risks while other ripe the benefits). Of course that 
such an approach should not limit the extension of the 
treatment to other groups that are more vulnerable (vul-
nerable patients should receive additional benefits com-
pared to non-vulnerable ones [56]).
Data sharing
Information from initial stages of the translational 
research process often appears in the headlines, suggest-
ing potential benefits well before the initiation of clini-
cal studies. A substance shown to diminish the number 
of cancer cells in cell cultures could be presented as a 
miraculous treatment for cancer. This dissemination 
could potentially pose risks, as patients with that disease 
could try on their own those substances, not yet proven 
to be effective in clinical studies. Therefore, the analy-
sis of potential consequences of published information 
from initial studies should also be performed in the early 
stages of translational research. If data considered sensi-
tive would be published in scientific journals, its presen-
tation should emphasize the not-ready-to-market status 
of the drug, and potential consequences of using it before 
there are established treatment guidelines. Moreover we 
should always take into account the risks of improper dis-
semination of information to the media (see the Wake-
field case [57] and its severe consequences regarding 
vaccination practices [58, 59]. Another risk with data 
obtained from translational research is its potential use 
for bioterrorism/military applications. For example, in 
2011 researchers from Japan to Netherlands announced 
the creation of a modified H5N1 influenza virus, which 
was transmissible through aerosols between ferrets; until 
that time, the virus was only known to be transmissible 
through direct contact with the infected animals. H5N1 
infects rarely humans, but the fatality rate is around 60 % 
[60]. Immediately after US intelligence analysts began 
to assess the potential security risks associated with the 
publication of those results. One of the most important 
elements of a scientific paper is reproducibility—other 
researchers, using the information from a specific arti-
cle, should be able to recreate the experiment, in order to 
test its validity. The researchers developing modified flu 
viruses should present enough data to make their experi-
ments reproducible. However, reproducibility also means 
that a virologist working for a terrorist organization could 
be able to reproduce the results. Ethically such a research 
is not publishable—if the researchers publish it, and the 
information is reproducible, there is a risk of bioterrorist 
applications; if the information is not reproducible, the 
article lacks clarity and its publication could be consid-
ered a form of scientific misconduct; if the researchers 
do not publish the article but perform the experiment, 
funds are wasted, and it could pose ethical issues regard-
ing resource allocation (especially if the research is publi-
cally funded. These risks should also be assessed before 
drafting the protocol for a translational research, and if 
the possibility for such misuses is high, we should try to 
perform an exhaustive risk–benefit ratio analysis for the 
whole translational research process.
Conclusions
The ethics of translational research should go beyond 
the classical topic of research ethics, or medical eth-
ics. It should not only analyse the ethical issues that can 
be directly derived from the translational phases but 
also those derived from the gaps between translational 
phases, transfer of knowledge and the particularities 
of translational research per se. There are many poten-
tial issues appertaining to the bioethics of translational 
research, of which only a few have been summarized 
in this article, and that should be reanalyzed within the 
translational research framework.
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